Home Blood Pressure in Hypertension Management

Antihypertensive Drug Treatment Decisions Based on Home Blood Pressure Monitoring

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00841308

Acronym

HBP10

Enrollment

150

Registered

2009-02-11

Start date

2009-02-28

Completion date

2012-12-31

Last updated

2012-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Brief summary

This is a prospective randomized study with two arms: the Conventional and Ambulatory blood pressure monitoring arm and the Home blood pressure monitoring arm. The study will include both previously treated and untreated individuals. Before randomization and in the end of the study, measurements will be performed using all three blood pressure monitoring methods (Conventional, Ambulatory and Home) as well as assessment of target organ damage (microalbuminuria, electrocardiogram, echocardiogram, carotid-femoral pulse wave velocity and central blood pressure). The participants will be randomized into one of the two arms. Diagnosis and titration will be decided according to either Conventional and Ambulatory blood pressure measurements or according to Home blood pressure measurements. Subjects will be followed up for one year.

Interventions

OTHERDecision to start and titrate drug treatment based only on home blood pressure monitoring

Drug Treatment according to current Hypertension Guidelines. Decision to start and titrate drug treatment based on clinic and ambulatory blood pressure (Usual care arm) versus based on home blood pressure monitoring only (Home blood pressure monitoring arm).

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

25 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Untreated hypertensive adults * Treated hypertensive adults with uncontrolled blood pressure

Exclusion criteria

* Stage III Hypertension * Secondary Hypertension * Cardiovascular or Renal disease * Uncontrolled Diabetes

Design outcomes

Primary

Measure	Time frame
Intermediate target organ damage (Left Ventricular Hypertrophy, Microalbuminuria, carotid-femoral Pulse Wave Velocity, Central blood pressure)	Baseline and 12 months

Secondary

Measure	Time frame
Blood Pressure Control, Cost-Effectiveness	Baseline and 12 months

Countries

Greece

Contacts

Primary ContactGeorge S Stergiou, MD

gstergi@med.uoa.gr+30 210 7763117

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026